Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma
about
Stem-like plasticity and heterogeneity of circulating tumor cells: current status and prospect challenges in liver cancerPalbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.FAM83D associates with high tumor recurrence after liver transplantation involving expansion of CD44+ carcinoma stem cells.Hedgehog signaling pathway affects the sensitivity of hepatoma cells to drug therapy through the ABCC1 transporter.IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell lines.Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals.Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma.Treatment options after sorafenib failure in patients with hepatocellular carcinoma.MiR-520f promotes cell aggressiveness by regulating fibroblast growth factor 16 in hepatocellular carcinoma.Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.Inhibition of insulin-like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival.Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet.
P2860
Q28079205-47BCCDA5-D254-4DFC-836B-82CAF08BA2C2Q33907588-B9D8FE2F-B5FD-43C8-AC6C-F655F8145174Q37718384-13020E01-1B16-4442-8CA4-03FEA90257D0Q38707438-D5970C51-45E2-4AE8-AB40-6B26AC523F42Q47101174-3F53C3D4-88AD-4FAA-AE4C-38FD54C86D51Q47161820-90A7C5AC-CF0A-4FA2-9DCF-F158E5E9345EQ47777680-7CD43404-3CB6-4A7F-8802-B7E1274F2F42Q47832831-1D5B749D-D3F7-4283-ADDF-C73911838121Q50129419-E5D3DB0B-3032-4D60-8582-B7E65255CD4FQ54111915-77F3D5E1-0DE0-4C7C-AB21-6DE08FB24F7DQ54976722-6A752C70-1C41-4ED1-AC41-ED623DFBD9C6Q55478812-877C61DC-F3FF-461C-8095-DF6BA3E20F3B
P2860
Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Tumour initiating cells and IG ...... ce in hepatocellular carcinoma
@en
type
label
Tumour initiating cells and IG ...... ce in hepatocellular carcinoma
@en
prefLabel
Tumour initiating cells and IG ...... ce in hepatocellular carcinoma
@en
P2093
P2860
P50
P1433
P1476
Tumour initiating cells and IG ...... ce in hepatocellular carcinoma
@en
P2093
Clara Alsinet
Daniela Sia
Helena Cornella
Iris Martinez-Quetglas
Josep Domingo-Domenech
Judit Peix
Laia Cabellos
Manel Solé
Samuel Vidal
Sara Torrecilla
P2860
P304
P356
10.1136/GUTJNL-2015-309501
P407
P577
2015-12-11T00:00:00Z